Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Myriad Genetics, Inc. (MYGN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1752)	1/6/2006 5:32:09 PM
From: zeta1961	Respond to of 2355

Rick, I'm just really catching up..thanx for posting the substance P material while I was gone.. Rick, the following is my comment on Flurbie[a heads up in case you want to click and move on!] I just noted today that they presented 12-15 month data and I also read the thread discussion here and Harry's opinion(thanks H!).. I won't belabor the issues of n in each group including the small n for follow-on..but indeed, looking at those graphs it seems to me that Flurbie is doing something here..something clinically relevant.. Secondly..I noticed that the placebo group suffered more serious neuro events than the Flurbie(urinary incontinence and psychiatric issues but they don't give the n) I spoke to MYGN today and unfortunately none of the science folk are presenting at JPMorgan..just Meldrum and the CFO.. Elisabeth.. clinically relevant in this case may be different from the confines of scientific rigor that we are accustomed in these trials?..